Today: 11 June 2026
Bitcoin price steadies above $70,000 as Trump-era crypto rally fades — and true believers won’t budge
8 February 2026
2 mins read

Bitcoin price steadies above $70,000 as Trump-era crypto rally fades — and true believers won’t budge

NEW YORK, Feb 8, 2026, 08:49 (EST)

Bitcoin circled $71,287 early Sunday, still holding over the $70,000 line after a turbulent week. The token’s 24/7 market means both the slide and bounce have carried straight into the weekend.

It’s a big deal in D.C. these days: President Donald Trump, back in the White House, has been touting plans to turn the U.S. into the “crypto capital of the world.” Lawmakers are following suit, pushing through looser regulations for some corners of the sector. Congress signed off on legislation for stablecoins — the dollar-linked digital tokens — as the industry keeps pressing into the financial mainstream. Still, bitcoin has lost ground. After almost doubling following Trump’s November 2024 win and reaching a high close to $126,000 last October, it’s fallen to about $60,000 this week. That’s now under where it stood when Trump reclaimed the presidency. “Bitcoin is anything but safe,” said Ben Schiffrin, senior policy director at Better Markets. NCPR

Some traders say the market structure is exaggerating the moves. “Reduced liquidity translates into sharper and more erratic price movements,” Kaiko research analyst Thomas Probst said, citing the decline in “market depth”—basically, how much can trade at current prices without causing swings. Denny Galindo at Morgan Stanley Wealth Management noted last fall’s flash crash “popped the leverage bubble.” CoinShares’ James Butterfill thinks markets may be “very close to a bottom,” even as Jefferies’ Andrew Moss still sees “few bullish indicators.” Reuters

Retail investors spent the week under pressure, following a pattern they know too well. Corey Geho, who’s been in since 2015, told MarketWatch, “Volatility is the price of admission.” He keeps buying on a fixed schedule, sticking to dollar-cost averaging — spreading his purchases out. Tayleb Brooks, 27, admitted the drop “hurts a little,” but said Wall Street’s push into futures and options — contracts for betting on price — is changing bitcoin’s draw. “Wall Street has many products that don’t” actually hold coins, he pointed out. John, a 75-year-old from California, summed it up differently: “seen this movie before.” MarketWatch

Leverage remains at the heart of the mess. Borrowed money fuels the rally, but when markets dip, those same trades unwind in a hurry—forced sales kick in, and selling pressure builds as margin calls hit.

Those who’ve been through crypto’s wild swings know to stay put during the downturns. “Crypto winter” sums it up—drawn-out slumps with falling prices, vanishing liquidity, and weaker hands forced out.

Crypto’s recent slide didn’t happen in isolation—it echoed broader market nerves. U.S. stocks snapped back Friday, with the Dow breaking above 50,000 for the first time. Bitcoin, after dipping near $60,000 late Thursday, was trading north of $70,000, according to the Associated Press. The AP also pointed to a rally in crypto-adjacent names like Coinbase, Robinhood, and Strategy, tracking gains in tech.

Still, calling this a textbook “risk-on” move is a stretch. Things could turn quickly. With scarce liquidity, it wouldn’t take much — maybe a policy jolt, a heavyweight unloading, or fresh anxiety about rates — to send bitcoin sliding back to the shaky levels that unsettled traders this week.

Washington is leaning pro-crypto, but the shift hasn’t fully filtered through markets yet. Investors are weighing whether newly friendly policy outweighs persistent wild swings. Bitcoin’s climbed above $70,000 again. Still, anyone betting on a smooth road ahead isn’t getting it.

Stock Market Today

  • EMCOR Group (EME) Shares Show 33.7% Undervaluation Despite Strong Price Gains
    June 11, 2026, 10:55 AM EDT. EMCOR Group's (EME) stock closed at $776.72, up 21.6% year to date and 64.9% over the last year, but recent dips have raised valuation questions. Using a Discounted Cash Flow (DCF) analysis-a method that projects future cash flows discounted to present value-Simply Wall St estimates an intrinsic value of $1,171.22 per share. This suggests the stock is trading at a 33.7% discount, indicating undervaluation despite recent market pullbacks. The company benefits from strong exposure to U.S. construction and infrastructure projects, supporting its growth outlook. Investors should consider these factors alongside valuation metrics like price-to-earnings ratios when assessing EMCOR's attractiveness amidst sector dynamics.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026
Previous Story

Windows 11 printer alert: Microsoft tightens the screws on legacy V3/V4 drivers in 2026

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open
Next Story

JPMorgan (JPM) stock price jumps nearly 4% as Dow tops 50,000 — what to watch before Monday’s open

Go toTop